MBL

CircuLex CML-HSA/Nε-(Carboxymethyl)lysine-HSA

Product Code:
 
MBL-CY-R2066
Product Group:
 
Recombinant Proteins
Supplier:
 
MBL
Regulatory Status:
 
RUO
Shipping:
 
dry ice
Storage:
 
-20°C
 

No additional charges, what you see is what you pay! *

CodeSizePrice
MBL-CY-R2066200 ug£285.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Background:
Reducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes. Although several AGE structures have been reported (1, 2), it was demonstrated that Nε-(carboxymethyl) lysine (CML) is a major antigenic AGE structure. CML concentration is also increased in patients who have diabetes with complications, including nephropathy (3?5), retinopathy (6), and atherosclerosis (7?9). CML is also recognized by receptor for AGE (RAGE), and CML-RAGE interaction activates cell signaling pathways such as NF-κB and enhances the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells (10).
Concentration:
1.0 mg/mL
Formulation:
The CML-HSA /Nε-(carboxymethyl) lysine-HSA is supplied frozen in a buffer containing 10mM PBS (pH 7.2).
Gene IDs:
Human: 5444 Mouse: 18979
Shelf Life:
1 year

Documents

References

(1) Ikeda K, et al.: Biochemistry 35: 8075 ?8083, 1996 (2) Reddy S, et al.: Biochemistry 34: 10872 ?10878, 1995 (3) Makino H, et al.: Kidney Int. 48: 517 ?526, 1995 (4) Suzuki D, et al.: J Diabetes Complications 10: 314 ?319, 1996 (5) Imai N, et al.: Nephron 76: 153 ?160, 1997 (6) Murata T, et al.: Diabetologia 40: 764 ?769, 1997 (7) Kume S, Takeya et al.: Am J Pathol. 147: 654 ?667, 1995 (8) Sakata N, et al.: Atherosclerosis 141: 61 ?75, 1998 (9) Sakata N, et al.: Atherosclerosis 142: 67 ?77, 1999 (10) Kislinger T, et al.: J. Biol. Chem. 274: 31740 ?31749, 1999